In Brief This Week: Qiagen, Mayo Clinic; Illumina; FDA, DNA Genotek; Agilent; NeoGenomics; Epigenomics; More | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen this week announced a partnership and licensing options with Mayo Clinic. The deal covers the use of the IDH1 and IDH2 biomarkers for diagnosing cholangiocarcinoma and guiding treatment for the disease, a rare form of cancer that affects between 2,000 and 3,000 patients each year in the US. The partners will collaborate on developing new IDH1/2 products for cholangiocarcinoma. Financial terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.